CNE000001C81
CNE000001C81
TASLY PHARMACEUTICAL GROUP CO L
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 |
|---|---|---|---|
Market & Enterprise Value | |||
Market Cap | 21.21B EUR | 19.76B EUR | 21.44B EUR |
Enterprise Value | 17.88B EUR | 19.24B EUR | 21.96B EUR |
Valuation Multiples | |||
Trailing P/E | 17.32x | 13.41x | 16.94x |
Forward P/E | 14.95x | -- | -- |
Price to Sales | 2.6x | 2.36x | 2.56x |
Price to Book | 1.62x | 1.51x | 1.68x |
EV/Revenue | 2.19x | 2.3x | 2.62x |
EV/EBITDA | 9.18x | 11.17x | 14.72x |
Price to FCF (P/FCF) | 15.25x | 7.78x | 15.41x |
EV/FCF | 12.85x | 7.58x | 15.78x |
FCF Yield | 6.56% | 12.85% | 6.49% |